alxoncology.com (ALXO): Debt to Equity

ALX Oncology Holdings (ALXO) is valued within the biotech sector for its deep expertise in CD47 blockade and the reliability of its developments. The business relies on the Evorpacept system, whose patents secure long-term partnerships with pharmaceutical behemoths. The brand's environmental policy includes a transition to green energy and emissions scrubbing. This price chart on GURU.Markets shows that the total debt-to-equity ratio is 0.08.

This ratio measures the proportion of borrowed liabilities to equity, determining the degree of financial autonomy and the risk of bankruptcy during liquidity shortages. For ALX Oncology (ALXO), which possesses a ready-made infrastructure and reserved capacities, the current total debt-to-equity ratio confirms the ability to fund the development of oncology complexes without placing a critical debt burden on capital.